绝经后荷尔蒙依赖性妇科癌症患者的激素替代疗法:叙述性综述
Paola Villa1, Valentina Elisabetta Bounous2, Inbal Dona Amar1
1Department of Women and Child's Health Sciences and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
激素替代疗法 (HRT) 可能是经历更年期的一些妇科癌症幸存者的选择. 与妇科瘤学家仔细讨论风险和益处是必不可少的.
科学领域:
- 妇科瘤学 妇科瘤学
- 生殖内分泌学 生殖内分泌学
- 瘤学 治疗学 治疗学
背景情况:
- 癌症治疗改善了生存率,但增加了更年期症状,特别是在过早更年期的年轻女性中.
- 过早的阳性更年期是接受妇科癌症治疗的年轻女性的一个重大问题.
研究的目的:
- 审查荷尔蒙替代疗法 (HRT) 的安全性和有效性,用于有荷尔蒙依赖性妇科癌症病史的患者.
- 为卵巢癌 (OC),宫腺癌 (AC) 和子宫内膜癌 (EC) 治疗后对HRT处方提供指导.
主要方法:
- 对现有文献进行了全面的叙事审查.
- 审查的重点是评估在患者中使用HRT的研究,OC,AC和EC.
主要成果:
- 对于早期,I-II级OC幸存者,有持续的绝经症状,对非激素疗法没有反应,可以考虑HRT.
- 在AC幸存者中,HRT没有禁忌,并且可以在手术后为早期,低度EC幸存者开处方.
- 对于特定的OC亚型 (血清边界瘤,子宫内膜组织OC),建议谨慎,对于低度的血清性OC,不建议HRT. 对于先进的EC,没有足够的数据.
结论:
- 在精选的妇科癌症患者中,HRT可以成为更年期症状的可行治疗选择.
- 在开始HRT之前,经验丰富的妇科瘤学家对个体化风险益处评估和咨询至关重要.
更多相关视频
09:48An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
07:20Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
相关概念视频
Menopause
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Disorders of the Female Reproductive System
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
Cancer Survival Analysis
